



## Clinical trial results:

### A phase I open-label multicentre dose-escalation study of subcutaneous ALM201 in patients with advanced ovarian cancer and other solid tumours.

#### Summary

EudraCT number	2014-001175-31
Trial protocol	GB
Global end of trial date	13 March 2017

#### Results information

Result version number	v1 (current)
This version publication date	02 March 2018
First version publication date	02 March 2018

#### Trial information

##### Trial identification

Sponsor protocol code	ALM201/0001
-----------------------	-------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03427073
WHO universal trial number (UTN)	-

Notes:

##### Sponsors

Sponsor organisation name	Almac Discovery
Sponsor organisation address	Centre for Precision, Therapeutics, Health Sciences Building, 97 Lisburn Road, Belfast, United Kingdom, BT9 7AE
Public contact	Professor Richard Kennedy, Medical Director, Almac Discovery, r.kennedy@qub.ac.uk
Scientific contact	Professor Richard Kennedy, Medical Director, Almac Discovery, r.kennedy@qub.ac.uk

Notes:

##### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	10 October 2017
Is this the analysis of the primary completion data?	Yes
Primary completion date	13 March 2017
Global end of trial reached?	Yes
Global end of trial date	13 March 2017
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

The primary objective was to characterise the safety and tolerability of ALM201 (Part 1 and Part 2) and to identify a recommended phase 2 dose (RP2D) and schedule of ALM201 (Part 2 only)

Protection of trial subjects:

This trial was conducted in compliance with International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines for conducting, recording, and reporting trials, as well as for archiving essential documents. No trial procedures were performed on trial participants until written consent had been obtained from them. The informed consent form (ICF), protocol, and amendments for this trial were submitted to and approved by the Ethics committee.

Routine monitoring was performed to verify that rights and well being of patients were protected. Also, any medication considered necessary for the patient's safety and well-being was given at the discretion of the Investigator.

Background therapy:

For treatment of DLT or any other clinically significant events, any available standard therapy was to be used as required. In the case of anaemia, transfusions with packed red blood cells (pRBC) were to be administered if required.

Local irritation at the injection site could be treated according to local treatment guidelines.

Evidence for comparator: -

Actual start date of recruitment	27 April 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 20
Worldwide total number of subjects	20
EEA total number of subjects	20

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	14
From 65 to 84 years	6
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Recruitment was carried out in three study sites in Belfast, Manchester and Newcastle, UK starting on 27 April 2015.

### Pre-assignment

Screening details:

Part 1 enrolled adult patients with advanced solid tumours in whom treatment with an anti-angiogenic agent was appropriate. Participants had screening evaluations between Day -1 and -28 before entering the first 21-day treatment cycle.

### Period 1

Period 1 title	overall study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Blinding implementation details:

This was an open label study.

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Cohort 1 - ALM201

Arm description:

One patient received 10 mg IMP from cycle 1 through cycle 6.

Arm type	Experimental
Investigational medicinal product name	ALM201
Investigational medicinal product code	ALM201
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Parenteral use

Dosage and administration details:

One vial contains 1.2 mL solution for injection containing 100mg/mL ALM201, 80 mM sodium carbonate, 20 mM Tris and 25 mM sodium chloride.

Route of administration: subcutaneous (SC)

The starting dose of ALM201 for cohort 1 was 10 mg per dose given on Days 1-5, 8-12 and 15-19 of a 21-day treatment cycle. In case of no DLT, the ALM201 dose was to be escalated for future cohorts in recommended increments according to the protocol.

<b>Arm title</b>	Cohort 2 - ALM201
------------------	-------------------

Arm description:

One patient received 20 mg IMP in cycle 1 and cycle 2.

Arm type	Experimental
Investigational medicinal product name	ALM201
Investigational medicinal product code	ALM201
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Parenteral use

Dosage and administration details:

One vial contains 1.2 mL solution for injection containing 100mg/mL ALM201, 80 mM sodium carbonate, 20 mM Tris and 25 mM sodium chloride.

Route of administration: subcutaneous (SC)

The patient was given 20 mg per dose on Days 1-5, 8-12 and 15-19 of a 21-day treatment cycle.

<b>Arm title</b>	Cohort 3 - ALM201
------------------	-------------------

Arm description:	
One patient received 40 mg IMP from cycle 1 through cycle 3.	
Arm type	Experimental
Investigational medicinal product name	ALM201
Investigational medicinal product code	ALM201
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Parenteral use
Dosage and administration details:	
One vial contains 1.2 mL solution for injection containing 100mg/mL ALM201, 80 mM sodium carbonate, 20 mM Tris and 25 mM sodium chloride.	
Route of administration: subcutaneous (SC)	
The patient received 40 mg per dose on Days 1-5, 8-12 and 15-19 of a 21-day treatment cycle.	
<b>Arm title</b>	Cohort 4 - ALM201

Arm description:	
Three patients received 80 mg IMP (3 patients during cycle 1, 2 patients in cycle 1 and cycle 2).	
Arm type	Experimental
Investigational medicinal product name	ALM201
Investigational medicinal product code	ALM201
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Parenteral use
Dosage and administration details:	
One vial contains 1.2 mL solution for injection containing 100mg/mL ALM201, 80 mM sodium carbonate, 20 mM Tris and 25 mM sodium chloride.	
Route of administration: subcutaneous (SC)	
Three patients received 80 mg per dose given on Days 1-5, 8-12 and 15-19 of a 21-day treatment cycle.	
<b>Arm title</b>	Cohort 5 - ALM201

Arm description:	
Three patients received 160 mg of IMP in cycles 1 and 2.	
Arm type	Experimental
Investigational medicinal product name	ALM201
Investigational medicinal product code	ALM201
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Parenteral use
Dosage and administration details:	
One vial contains 1.2 mL solution for injection containing 100mg/mL ALM201, 80 mM sodium carbonate, 20 mM Tris and 25 mM sodium chloride.	
Route of administration: subcutaneous (SC)	
3 patients were given a dose of 160 mg on Days 1-5, 8-12 and 15-19 of a 21-day treatment cycle.	
<b>Arm title</b>	Cohort 6 - ALM201

Arm description:	
Four patients received 200 mg IMP in cycle 1; 3 patients in cycle 1 and 2, 2 patients in cycle 1 through 4 and one patient in cycle 1 through 5.	
Arm type	Experimental
Investigational medicinal product name	ALM201
Investigational medicinal product code	ALM201
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Parenteral use
Dosage and administration details:	
One vial contains 1.2 mL solution for injection containing 100mg/mL ALM201, 80 mM sodium carbonate,	

20 mM Tris and 25 mM sodium chloride.

Route of administration: subcutaneous (SC)

Cohort 6 was given 200 mg on Days 1-5, 8-12 and 15-19 of a 21-day treatment cycle.

<b>Arm title</b>	Cohort 7 - ALM201
Arm description: Three patients received 300 mg IMP in cycle 1 and 2; one of them received the IMP in cycle 1 through cycle 6.	
Arm type	Experimental
Investigational medicinal product name	ALM201
Investigational medicinal product code	ALM201
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Parenteral use

Dosage and administration details:

One vial contains 1.2 mL solution for injection containing 100mg/mL ALM201, 80 mM sodium carbonate, 20 mM Tris and 25 mM sodium chloride.

Route of administration: subcutaneous (SC)

Cohort 7 was given 300 mg IMP on Days 1-5, 8-12 and 15-19 of a 21-day treatment cycle.

<b>Arm title</b>	Cohort 8 - ALM201
Arm description: Four patients received 100 mg IMP in cycle 1; two of them completed cycle 2.	
Arm type	Experimental
Investigational medicinal product name	ALM201
Investigational medicinal product code	ALM201
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Parenteral use

Dosage and administration details:

One vial contains 1.2 mL solution for injection containing 100mg/mL ALM201, 80 mM sodium carbonate, 20 mM Tris and 25 mM sodium chloride.

Route of administration: subcutaneous (SC)

Cohort 8 was given 100 mg per dose on Days 1-5, 8-12 and 15-19 of a 21-day treatment cycle.

<b>Number of subjects in period 1</b>	Cohort 1 - ALM201	Cohort 2 - ALM201	Cohort 3 - ALM201
Started	1	1	1
Completed	0	0	0
Not completed	1	1	1
Physician decision	-	-	-
disease progression	1	1	1

<b>Number of subjects in period 1</b>	Cohort 4 - ALM201	Cohort 5 - ALM201	Cohort 6 - ALM201
Started	3	3	4
Completed	0	0	0
Not completed	3	3	4
Physician decision	-	-	-

disease progression	3	3	4
---------------------	---	---	---

<b>Number of subjects in period 1</b>	Cohort 7 - ALM201	Cohort 8 - ALM201
Started	3	4
Completed	0	0
Not completed	3	4
Physician decision	1	1
disease progression	2	3

## Baseline characteristics

### Reporting groups

Reporting group title	overall study
-----------------------	---------------

Reporting group description: -

Reporting group values	overall study	Total	
Number of subjects	20	20	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	14	14	
From 65-84 years	6	6	
85 years and over	0	0	
Gender categorical			
Units: Subjects			
Female	12	12	
Male	8	8	
Ethnic origin			
Units: Subjects			
white	20	20	

## End points

### End points reporting groups

Reporting group title	Cohort 1 - ALM201
Reporting group description:	One patient received 10 mg IMP from cycle 1 through cycle 6.
Reporting group title	Cohort 2 - ALM201
Reporting group description:	One patient received 20 mg IMP in cycle 1 and cycle 2.
Reporting group title	Cohort 3 - ALM201
Reporting group description:	One patient received 40 mg IMP from cycle 1 through cycle 3.
Reporting group title	Cohort 4 - ALM201
Reporting group description:	Three patients received 80 mg IMP (3 patients during cycle 1, 2 patients in cycle 1 and cycle 2).
Reporting group title	Cohort 5 - ALM201
Reporting group description:	Three patients received 160 mg of IMP in cycles 1 and 2.
Reporting group title	Cohort 6 - ALM201
Reporting group description:	Four patients received 200 mg IMP in cycle 1; 3 patients in cycle 1 and 2, 2 patients in cycle 1 through 4 and one patient in cycle 1 through 5.
Reporting group title	Cohort 7 - ALM201
Reporting group description:	Three patients received 300 mg IMP in cycle 1 and 2; one of them received the IMP in cycle 1 through cycle 6.
Reporting group title	Cohort 8 - ALM201
Reporting group description:	Four patients received 100 mg IMP in cycle 1; two of them completed cycle 2.

### Primary: Safety and tolerability - evaluation of AEs and DLT

End point title	Safety and tolerability - evaluation of AEs and DLT <sup>[1]</sup>
End point description:	<p>All events and suspected dose limiting toxicities (DLTs) were graded according to the CTCAE, version 4.03.</p> <p>A DLT was defined as a Grade 3 or 4 AE that, in the opinion of the CRC, was likely to be related to ALM201 and represented a clinically significant hazard to the patient. Qualifying DLT events were considered to be clinically relevant; e.g. in duration, apparent reversibility, required management, and upon consideration of the patient's medical history and/or concomitant medications. DLT events were also evaluated in terms of what was considered to be an appropriate next escalation step: In the case where the CRC agreed that an escalation step of approximately 33% or lower was merited; the toxicity of concern could be declared a DLT.</p> <p>In order to be evaluable for DLT assessment, a patient had to receive at least 80% of their scheduled doses (e.g. 12 of the 15), unless this lack of compliance was due to ALM201-related toxicity.</p>
End point type	Primary
End point timeframe:	Adverse event evaluation was done during treatment and follow-up. DLT evaluation was done during cycle 1.
Notes:	<p>[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.</p> <p>Justification: No inferential statistical analysis was performed for this primary endpoint.</p>

<b>End point values</b>	Cohort 1 - ALM201	Cohort 2 - ALM201	Cohort 3 - ALM201	Cohort 4 - ALM201
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	1	1	3
Units: Number of patients				
TEAE	1	0	1	3
treatment related TEAE	1	0	1	1
DLT	0	0	0	0
SAE	1	0	0	1
treatment related SAE	0	0	0	0

<b>End point values</b>	Cohort 5 - ALM201	Cohort 6 - ALM201	Cohort 7 - ALM201	Cohort 8 - ALM201
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	4	3	4
Units: Number of patients				
TEAE	3	4	3	4
treatment related TEAE	3	4	3	2
DLT	0	0	0	0
SAE	1	2	0	1
treatment related SAE	0	0	0	1

### Statistical analyses

No statistical analyses for this end point

### Secondary: Tumour response assessment

End point title	Tumour response assessment
-----------------	----------------------------

End point description:

As this was a Phase 1 study, the extent of efficacy data was expected to be limited. A summary of clinical benefit, by RECIST Version 1.1 from patients with evaluable disease was generated.

End point type	Secondary
----------------	-----------

End point timeframe:

Response assessments were done to assess clinical benefit in the efficacy population overall and at the end of cycles 2, 4 and 6, as applicable

<b>End point values</b>	Cohort 1 - ALM201	Cohort 2 - ALM201	Cohort 3 - ALM201	Cohort 4 - ALM201
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	1	1	3
Units: number of patients				
Complete Response (CR)	0	0	0	0
Partial Response (PR)	0	0	0	0
Overall Response Rate (CR+PR)	0	0	0	0
Stable Disease (SD)	1	0	1	0

Disease Control Rate (CR+PR+SD)	1	0	1	0
Progressive Disease	0	1	0	3
Not Evaluable (NE+NA)	0	0	0	0

<b>End point values</b>	Cohort 5 - ALM201	Cohort 6 - ALM201	Cohort 7 - ALM201	Cohort 8 - ALM201
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	4	3	4
Units: number of patients				
Complete Response (CR)	0	0	0	0
Partial Response (PR)	0	0	0	0
Overall Response Rate (CR+PR)	0	0	0	0
Stable Disease (SD)	0	2	2	1
Disease Control Rate (CR+PR+SD)	0	2	2	1
Progressive Disease	3	1	1	3
Not Evaluable (NE+NA)	0	1	0	0

### Statistical analyses

No statistical analyses for this end point

### Secondary: Pharmacokinetics

End point title	Pharmacokinetics
End point description:	Only data from cycles 1 and 2 are presented, since data for cycles 4 and 6 are not available for all cohorts.
End point type	Secondary
End point timeframe:	Tmax was determined in cycles 1, 2, 4 and 6 of treatment.

<b>End point values</b>	Cohort 1 - ALM201	Cohort 2 - ALM201	Cohort 3 - ALM201	Cohort 4 - ALM201
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	1	1	3 <sup>[2]</sup>
Units: Tmax (h)				
median (full range (min-max))				
Cycle 1 - Day 1	1.45 (1.45 to 1.45)	1.50 (1.50 to 1.50)	1.63 (1.63 to 1.63)	1.53 (0.75 to 2.0)
Cycle 1 - Day 3	0.50 (0.50 to 0.50)	1.00 (1.00 to 1.00)	1.50 (1.50 to 1.50)	1.50 (1.05 to 2.0)
Cycle 1 - Day 18	1.58 (1.58 to 1.58)	1.02 (1.02 to 1.02)	1.00 (1.00 to 1.00)	1.23 (0.47 to 2.0)
Cycle 2 - Day 18	2.00 (2.00 to 2.00)	1.00 (1.00 to 1.00)	1.03 (1.03 to 1.03)	3.50 (3.50 to 3.50)

Notes:

[2] - 2 patients on Cycle 1 - Day 18; 1 patient on Cycle 2 - Day 18

<b>End point values</b>	Cohort 5 - ALM201	Cohort 6 - ALM201	Cohort 7 - ALM201	Cohort 8 - ALM201
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3 <sup>[3]</sup>	4 <sup>[4]</sup>	3	4 <sup>[5]</sup>
Units: Tmax (h)				
median (full range (min-max))				
Cycle 1 - Day 1	1.52 (0.80 to 3.07)	2.50 (1.50 to 3.08)	2.00 (0.75 to 4.00)	1.50 (1.30 to 1.50)
Cycle 1 - Day 3	1.52 (1.52 to 2.05)	2.00 (1.48 to 2.00)	1.02 (1.00 to 2.00)	1.61 (0.50 to 2.02)
Cycle 1 - Day 18	1.50 (0.50 to 2.00)	2.03 (1.00 to 3.50)	1.50 (1.00 to 2.07)	1.90 (1.45 to 2.35)
Cycle 2 - Day 18	2.00 (2.00 to 2.00)	1.54 (1.50 to 1.58)	2.00 (1.48 to 2.13)	1.02 (1.02 to 1.02)

Notes:

[3] - 1 patient on Cycle 2 - Day 18

[4] - 3 patients on Cycle 1 - Day 18; 2 patients on Cycle 2 - Day 18

[5] - 2 patients on Cycle 1 - Day 18; 1 patient on Cycle 2 - Day 18

## Statistical analyses

No statistical analyses for this end point

## Secondary: Pharmacokinetics

End point title	Pharmacokinetics
-----------------	------------------

End point description:

Only data from cycles 1 and 2 are presented, since data for cycles 4 and 6 are not available for all cohorts.

End point type	Secondary
----------------	-----------

End point timeframe:

AUC 0-t was determined in cycles 1, 2, 4 and 6 of treatment.

<b>End point values</b>	Cohort 1 - ALM201	Cohort 2 - ALM201	Cohort 3 - ALM201	Cohort 4 - ALM201
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	1	1	3 <sup>[6]</sup>
Units: AUC0-t (ng.h/mL)				
geometric mean (full range (min-max))				
Cycle 1 - Day 1	485 (485 to 485)	1040 (1040 to 1040)	1920 (1920 to 1920)	3380 (3100 to 3790)
Cycle 1 - Day 3	868 (868 to 868)	1160 (1160 to 1160)	898 (898 to 898)	2970 (2660 to 3430)
Cycle 1 - Day 18	817 (817 to 817)	718 (718 to 718)	1840 (1840 to 1840)	3500 (3440 to 3570)
Cycle 2 - Day 18	702 (702 to 702)	1020 (1020 to 1020)	1950 (1950 to 1950)	3230 (3230 to 3230)

Notes:

[6] - 2 patients on Cycle 1 - Day 18; 1 patient on Cycle 2 - Day 18

<b>End point values</b>	Cohort 5 - ALM201	Cohort 6 - ALM201	Cohort 7 - ALM201	Cohort 8 - ALM201
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3 <sup>[7]</sup>	4 <sup>[8]</sup>	3	4 <sup>[9]</sup>
Units: AUC <sub>0-t</sub> (ng.h/mL)				
geometric mean (full range (min-max))				
Cycle 1 - Day 1	6510 (5600 to 7560)	5860 (3460 to 10200)	11900 (9470 to 15100)	6280 (1140 to 14800)
Cycle 1 - Day 3	5100 (4970 to 5280)	6630 (4460 to 11900)	12500 (10500 to 14700)	8870 (5380 to 12800)
Cycle 1 - Day 18	4930 (4400 to 5400)	5570 (3900 to 10000)	12100 (11400 to 12900)	8100 (7000 to 9370)
Cycle 2 - Day 18	5710 (5710 to 5710)	5680 (3810 to 8480)	10400 (7290 to 16700)	5930 (5930 to 5930)

Notes:

[7] - 1 patient on Cycle 2 - Day 18

[8] - 3 patients on Cycle 1 - Day 18; 2 patients on Cycle 2 - Day 18

[9] - 2 patients on Cycle 1 - Day 18; 1 patient on Cycle 2 - Day 18

## Statistical analyses

No statistical analyses for this end point

## Secondary: Pharmacokinetics

End point title	Pharmacokinetics
End point description:	Only data from cycles 1 and 2 are presented, since data for cycles 4 and 6 are not available for all cohorts.
End point type	Secondary
End point timeframe:	C <sub>max</sub> of ALM201 following subcutaneous (SC) administration of ALM201 was determined in cycles 1, 2, 4 and 6 of treatment.

<b>End point values</b>	Cohort 1 - ALM201	Cohort 2 - ALM201	Cohort 3 - ALM201	Cohort 4 - ALM201
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	1	1	3 <sup>[10]</sup>
Units: C <sub>max</sub> (ng/mL)				
geometric mean (full range (min-max))				
Cycle 1 - Day 1	200 (200 to 200)	542 (542 to 542)	592 (592 to 592)	835 (749 to 892)
Cycle 1 - Day 3	406 (406 to 406)	614 (614 to 614)	759 (759 to 759)	861 (762 to 1090)
Cycle 1 - Day 18	352 (352 to 352)	319 (319 to 319)	405 (405 to 405)	1090 (1090 to 1100)
Cycle 2 - Day 18	288 (288 to 288)	394 (394 to 394)	583 (583 to 583)	849 (849 to 849)

Notes:

[10] - 2 patients on Cycle 1 - Day 18; 1 patient on Cycle 2 - Day 18

<b>End point values</b>	Cohort 5 - ALM201	Cohort 6 - ALM201	Cohort 7 - ALM201	Cohort 8 - ALM201
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3 <sup>[11]</sup>	4 <sup>[12]</sup>	3	4 <sup>[13]</sup>
Units: Cmax (ng/mL)				
geometric mean (full range (min-max))				
Cycle 1 - Day 1	1990 (1730 to 2190)	1490 (890 to 2690)	2550 (2100 to 3650)	1810 (465 to 4600)
Cycle 1 - Day 3	1490 (1390 to 1660)	1620 (1160 to 3100)	2690 (2300 to 3260)	2750 (1450 to 4280)
Cycle 1 - Day 18	1350 (1240 to 1420)	1670 (1230 to 2880)	2880 (2420 to 3450)	2330 (2140 to 2530)
Cycle 2 - Day 18	1870 (1870 to 1870)	1890 (1280 to 2790)	2780 (2110 to 4310)	1790 (1790 to 1790)

Notes:

[11] - 1 patient on Cycle 2 - Day 18

[12] - 3 patients on Cycle 1 - Day 18; 2 patients on Cycle 2 - Day 18

[13] - 2 patients on Cycle 1 - Day 18; 1 patient on Cycle 2 - Day 18

### **Statistical analyses**

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Ongoing during treatment and follow-up

Adverse event reporting additional description:

During the study, AEs were spontaneously reported or elicited during open-ended questioning, examination, or evaluation of a patient.

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	17.0
--------------------	------

### Reporting groups

Reporting group title	Cohort 1 - ALM201
-----------------------	-------------------

Reporting group description:

One patient received 10 mg IMP from cycle 1 through cycle 6.

Reporting group title	Cohort 2 - ALM201
-----------------------	-------------------

Reporting group description:

One patient received 20 mg IMP in cycle 1 and cycle 2.

Reporting group title	Cohort 3 - ALM201
-----------------------	-------------------

Reporting group description:

One patient received 40 mg IMP from cycle 1 through cycle 3.

Reporting group title	Cohort 4 - ALM201
-----------------------	-------------------

Reporting group description:

Three patients received 80 mg IMP (3 patients during cycle 1, 2 patients in cycle 1 and cycle 2).

Reporting group title	Cohort 6 - ALM201
-----------------------	-------------------

Reporting group description:

Four patients received 200 mg IMP in cycle 1; 3 patients in cycle 1 and 2, 2 patients in cycle 1 through 4 and one patient in cycle 1 through 5.

Reporting group title	Cohort 7 - ALM201
-----------------------	-------------------

Reporting group description:

Three patients received 300 mg IMP in cycle 1 and 2; one of them received the IMP in cycle 1 through cycle 6.

Reporting group title	Cohort 8 - ALM201
-----------------------	-------------------

Reporting group description:

Four patients received 100 mg IMP in cycle 1; two of them completed cycle 2.

Reporting group title	Cohort 5 - ALM201
-----------------------	-------------------

Reporting group description:

Three patients received 160 mg of IMP in cycles 1 and 2.

<b>Serious adverse events</b>	Cohort 1 - ALM201	Cohort 2 - ALM201	Cohort 3 - ALM201
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 1 (100.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
General disorders and administration site conditions			

Device occlusion			
subjects affected / exposed	1 / 1 (100.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	1 / 1 (100.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Large intestinal obstruction			
subjects affected / exposed	1 / 1 (100.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis acute			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Pulmonary embolism			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Renal vein thrombosis			
subjects affected / exposed	1 / 1 (100.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Lower respiratory tract infection			

subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Cohort 4 - ALM201	Cohort 6 - ALM201	Cohort 7 - ALM201
<b>Total subjects affected by serious adverse events</b>			
subjects affected / exposed	1 / 3 (33.33%)	2 / 4 (50.00%)	0 / 3 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
<b>General disorders and administration site conditions</b>			
Device occlusion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gastrointestinal disorders</b>			
Large intestinal obstruction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Hepatobiliary disorders</b>			
Cholecystitis acute			

subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Respiratory, thoracic and mediastinal disorders</b>			
Pulmonary embolism			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Renal and urinary disorders</b>			
Renal vein thrombosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Infections and infestations</b>			
Lower respiratory tract infection			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Cohort 8 - ALM201	Cohort 5 - ALM201	
<b>Total subjects affected by serious adverse events</b>			
subjects affected / exposed	1 / 4 (25.00%)	1 / 3 (33.33%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
<b>General disorders and administration site conditions</b>			
Device occlusion			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			

subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Gastrointestinal disorders</b>			
Large intestinal obstruction			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal obstruction			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Hepatobiliary disorders</b>			
Cholecystitis acute			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Respiratory, thoracic and mediastinal disorders</b>			
Pulmonary embolism			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Renal and urinary disorders</b>			
Renal vein thrombosis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Infections and infestations</b>			
Lower respiratory tract infection			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral infection			

subjects affected / exposed	0 / 4 (0.00%)	1 / 3 (33.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0.05 %

<b>Non-serious adverse events</b>	Cohort 1 - ALM201	Cohort 2 - ALM201	Cohort 3 - ALM201
Total subjects affected by non-serious adverse events			
subjects affected / exposed	1 / 1 (100.00%)	0 / 1 (0.00%)	1 / 1 (100.00%)
Vascular disorders			
Hot flush			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Thrombosis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Chest discomfort			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Device occlusion			
subjects affected / exposed	1 / 1 (100.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Fatigue			
subjects affected / exposed	1 / 1 (100.00%)	0 / 1 (0.00%)	1 / 1 (100.00%)
occurrences (all)	1	0	1
Injection site bruising			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Injection site erythema			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Injection site pain			
subjects affected / exposed	1 / 1 (100.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Injection site pruritus			

subjects affected / exposed occurrences (all)	1 / 1 (100.00%) 1	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Injection site rash subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Injection site reaction subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Non-cardiac chest pain subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Oedema peripheral subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	1 / 1 (100.00%) 1
Pyrexia subjects affected / exposed occurrences (all)	1 / 1 (100.00%) 1	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Reproductive system and breast disorders Scrotal swelling subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Vaginal haemorrhage subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Dyspnoea subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	1 / 1 (100.00%) 1
Pulmonary embolism subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Wheezing			

subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Psychiatric disorders			
Confusional state			
subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Depressed mood			
subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Depression			
subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	1 / 1 (100.00%) 1
Insomnia			
subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Investigations			
Aspartate aminotransferase increased			
subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Blood alkaline phosphatase increased			
subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Blood bilirubin increased			
subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Blood creatinine increased			
subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Urine output decreased			
subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Weight decreased			
subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Injury, poisoning and procedural complications			

Catheter site pain subjects affected / exposed occurrences (all)	1 / 1 (100.00%) 1	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Contusion subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Excoriation subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Fall subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Procedural pain subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Cardiac disorders Conduction disorder subjects affected / exposed occurrences (all)	1 / 1 (100.00%) 1	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Tachycardia subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Nervous system disorders Aphasia subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Dizziness subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Dysgeusia subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	1 / 1 (100.00%) 1
Headache subjects affected / exposed occurrences (all)	1 / 1 (100.00%) 1	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Memory impairment			

subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Neuralgia subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	1 / 1 (100.00%) 1
Neuropathy peripheral subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Eye disorders Vision blurred subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Gastrointestinal disorders Abdominal pain subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Abdominal pain upper subjects affected / exposed occurrences (all)	1 / 1 (100.00%) 1	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Ascites subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Constipation subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	1 / 1 (100.00%) 1
Diarrhoea subjects affected / exposed occurrences (all)	1 / 1 (100.00%) 1	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Dyspepsia subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Flatulence			

subjects affected / exposed occurrences (all)	1 / 1 (100.00%) 1	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Haemorrhoidal haemorrhage subjects affected / exposed occurrences (all)	1 / 1 (100.00%) 1	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Large intestinal obstruction subjects affected / exposed occurrences (all)	1 / 1 (100.00%) 1	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Lip swelling subjects affected / exposed occurrences (all)	1 / 1 (100.00%) 1	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Nausea subjects affected / exposed occurrences (all)	1 / 1 (100.00%) 1	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Rectal haemorrhage subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Small intestinal obstruction subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Stomatitis subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	1 / 1 (100.00%) 1
Vomiting subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Hepatobiliary disorders Cholecystitis acute subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Skin and subcutaneous tissue disorders Alopecia subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Dry skin			

subjects affected / exposed	1 / 1 (100.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Erythema			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Rash erythematous			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Rash macular			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Renal failure acute			
subjects affected / exposed	1 / 1 (100.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Renal vein thrombosis			
subjects affected / exposed	1 / 1 (100.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Urinary retention			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	1 / 1 (100.00%)
occurrences (all)	0	0	1
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 1 (100.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Flank pain			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	1 / 1 (100.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Musculoskeletal chest pain			

subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	1 / 1 (100.00%)
occurrences (all)	0	0	1
Neck pain			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	1 / 1 (100.00%)
occurrences (all)	0	0	1
Back pain			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Lower respiratory tract infection			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Oral candidiasis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	1 / 1 (100.00%)
occurrences (all)	0	0	1
Oral fungal infection			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Skin infection			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	1 / 1 (100.00%)
occurrences (all)	0	0	1
Urinary tract infection enterococcal			
subjects affected / exposed	1 / 1 (100.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0

Viral infection subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Metabolism and nutrition disorders Decreased appetite subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	1 / 1 (100.00%) 1
Hypophosphataemia subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0

<b>Non-serious adverse events</b>	Cohort 4 - ALM201	Cohort 6 - ALM201	Cohort 7 - ALM201
Total subjects affected by non-serious adverse events subjects affected / exposed	3 / 3 (100.00%)	4 / 4 (100.00%)	3 / 3 (100.00%)
Vascular disorders Hot flush subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	1 / 3 (33.33%) 1
Thrombosis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0
General disorders and administration site conditions Chest discomfort subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0
Device occlusion subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0
Fatigue subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	2 / 4 (50.00%) 2	2 / 3 (66.67%) 2
Injection site bruising subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	2 / 4 (50.00%) 2	2 / 3 (66.67%) 2
Injection site erythema subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0

Injection site pain subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0
Injection site pruritus subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0
Injection site rash subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	1 / 3 (33.33%) 1
Injection site reaction subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	1 / 4 (25.00%) 1	2 / 3 (66.67%) 2
Non-cardiac chest pain subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	0 / 4 (0.00%) 0	1 / 3 (33.33%) 0
Oedema peripheral subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	2 / 4 (50.00%) 2	0 / 3 (0.00%) 0
Pyrexia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0
Reproductive system and breast disorders			
Scrotal swelling subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	1 / 3 (33.33%) 1
Vaginal haemorrhage subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	1 / 3 (33.33%) 1
Respiratory, thoracic and mediastinal disorders			
Cough subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 4 (25.00%) 1	1 / 3 (33.33%) 1
Dyspnoea subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0
Pulmonary embolism			

subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0
Wheezing subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0
Psychiatric disorders Confusional state subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 4 (25.00%) 1	0 / 3 (0.00%) 0
Depressed mood subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0
Depression subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0
Insomnia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0
Investigations Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0
Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0
Blood bilirubin increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0
Blood creatinine increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0
Urine output decreased subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0
Weight decreased			

subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	1 / 3 (33.33%) 1
<b>Injury, poisoning and procedural complications</b>			
Catheter site pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Contusion			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Excoriation			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Fall			
subjects affected / exposed	0 / 3 (0.00%)	2 / 4 (50.00%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Procedural pain			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
<b>Cardiac disorders</b>			
Conduction disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Tachycardia			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
<b>Nervous system disorders</b>			
Aphasia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Dizziness			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Dysgeusia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Headache			

subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	1 / 3 (33.33%) 1
Memory impairment subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 4 (25.00%) 1	0 / 3 (0.00%) 0
Neuralgia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0
Neuropathy peripheral subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	1 / 4 (25.00%) 1	0 / 3 (0.00%) 0
Eye disorders Vision blurred subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0
Gastrointestinal disorders Abdominal pain subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 4 (25.00%) 1	1 / 3 (33.33%) 1
Abdominal pain upper subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 4 (25.00%) 1	0 / 3 (0.00%) 0
Ascites subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0
Constipation subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0
Diarrhoea subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	2 / 4 (50.00%) 2	0 / 3 (0.00%) 0
Dyspepsia			

subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Flatulence			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Large intestinal obstruction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lip swelling			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	1 / 3 (33.33%)
occurrences (all)	0	1	1
Rectal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Small intestinal obstruction			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Stomatitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Hepatobiliary disorders			
Cholecystitis acute			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Skin and subcutaneous tissue disorders			
Alopecia			

subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 4 (25.00%) 1	0 / 3 (0.00%) 0
Dry skin subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0
Erythema subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	2 / 4 (50.00%) 2	0 / 3 (0.00%) 0
Pruritus subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0
Rash erythematous subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0
Rash macular subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0
Renal and urinary disorders Renal failure acute subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0
Renal vein thrombosis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0
Urinary retention subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	0 / 4 (0.00%) 0	1 / 3 (33.33%) 1
Flank pain subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0
Muscle spasms			

subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Musculoskeletal pain			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Neck pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Back pain			
subjects affected / exposed	2 / 3 (66.67%)	0 / 4 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
Infections and infestations			
Lower respiratory tract infection			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Oral candidiasis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oral fungal infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Skin infection			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	1 / 3 (33.33%)
occurrences (all)	0	1	1
Urinary tract infection			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 3 (0.00%)
occurrences (all)	0	1	0

Urinary tract infection enterococcal subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0
Viral infection subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	2 / 4 (50.00%) 2	1 / 3 (33.33%) 1
Hypophosphataemia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0

<b>Non-serious adverse events</b>	Cohort 8 - ALM201	Cohort 5 - ALM201	
Total subjects affected by non-serious adverse events subjects affected / exposed	4 / 4 (100.00%)	3 / 3 (100.00%)	
Vascular disorders			
Hot flush subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	
Thrombosis subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 3 (0.00%) 0	
General disorders and administration site conditions			
Chest discomfort subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 3 (33.33%) 1	
Device occlusion subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	
Fatigue subjects affected / exposed occurrences (all)	2 / 4 (50.00%) 2	1 / 3 (33.33%) 1	
Injection site bruising subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	1 / 3 (33.33%) 1	

Injection site erythema subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	1 / 3 (33.33%) 1	
Injection site pain subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	
Injection site pruritus subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	
Injection site rash subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	
Injection site reaction subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	
Non-cardiac chest pain subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	
Oedema peripheral subjects affected / exposed occurrences (all)	2 / 4 (50.00%) 2	0 / 3 (0.00%) 0	
Pyrexia subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	1 / 3 (33.33%) 1	
Reproductive system and breast disorders			
Scrotal swelling subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	
Vaginal haemorrhage subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	1 / 3 (33.33%) 1	
Respiratory, thoracic and mediastinal disorders			
Cough subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 3 (33.33%) 1	
Dyspnoea			

subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	1 / 3 (33.33%) 1	
Pulmonary embolism subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 3 (0.00%) 0	
Wheezing subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 3 (33.33%) 1	
Psychiatric disorders			
Confusional state subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	
Depressed mood subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 3 (33.33%) 1	
Depression subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	
Insomnia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 3 (33.33%) 1	
Investigations			
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 3 (0.00%) 0	
Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 3 (0.00%) 0	
Blood bilirubin increased subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 3 (0.00%) 0	
Blood creatinine increased subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 3 (0.00%) 0	
Urine output decreased			

subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	
Weight decreased subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	
Injury, poisoning and procedural complications			
Catheter site pain subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	
Contusion subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 3 (0.00%) 0	
Excoriation subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	
Fall subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	
Procedural pain subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	
Cardiac disorders			
Conduction disorder subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	
Tachycardia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	
Nervous system disorders			
Aphasia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	
Dizziness subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 3 (0.00%) 0	
Dysgeusia			

subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	
Headache subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	2 / 3 (66.67%) 2	
Memory impairment subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	
Neuralgia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	
Neuropathy peripheral subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	1 / 3 (33.33%) 1	
Eye disorders Vision blurred subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 3 (33.33%) 1	
Gastrointestinal disorders Abdominal pain subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 3 (33.33%) 1	
Abdominal pain upper subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	
Ascites subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 3 (33.33%) 1	
Constipation subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 3 (33.33%) 1	
Diarrhoea			

subjects affected / exposed	0 / 4 (0.00%)	1 / 3 (33.33%)	
occurrences (all)	0	1	
Dyspepsia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 3 (33.33%)	
occurrences (all)	0	1	
Flatulence			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Large intestinal obstruction			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Lip swelling			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Nausea			
subjects affected / exposed	0 / 4 (0.00%)	2 / 3 (66.67%)	
occurrences (all)	0	2	
Rectal haemorrhage			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	
occurrences (all)	1	0	
Small intestinal obstruction			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Stomatitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Vomiting			
subjects affected / exposed	0 / 4 (0.00%)	1 / 3 (33.33%)	
occurrences (all)	0	1	
Hepatobiliary disorders			
Cholecystitis acute			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	

Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Dry skin			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Erythema			
subjects affected / exposed	0 / 4 (0.00%)	1 / 3 (33.33%)	
occurrences (all)	0	1	
Pruritus			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	
occurrences (all)	1	0	
Rash erythematous			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	
occurrences (all)	1	0	
Rash macular			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	
occurrences (all)	1	0	
Renal and urinary disorders			
Renal failure acute			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Renal vein thrombosis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Urinary retention			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	
occurrences (all)	0	0	
Flank pain			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	
occurrences (all)	1	0	

Muscle spasms subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	
Musculoskeletal chest pain subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 3 (0.00%) 0	
Musculoskeletal pain subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	
Neck pain subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	
Back pain subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	1 / 3 (33.33%) 1	
Infections and infestations			
Lower respiratory tract infection subjects affected / exposed occurrences (all)	2 / 4 (50.00%) 2	0 / 3 (0.00%) 0	
Oral candidiasis subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	
Oral fungal infection subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 3 (0.00%) 0	
Respiratory tract infection subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	
Skin infection subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	
Upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	
Urinary tract infection			

subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 3 (0.00%) 0	
Urinary tract infection enterococcal subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	
Viral infection subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 3 (33.33%) 1	
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	2 / 4 (50.00%) 2	0 / 3 (0.00%) 0	
Hypophosphataemia subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 3 (0.00%) 0	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

It was decided not to proceed with Part 2 of the study as several preclinical studies running in parallel did not support the hypothesis around the biomarker strategy for the selection of patients for Part 2.
--

Notes:

---

### Online references

<http://www.ncbi.nlm.nih.gov/pubmed/19097774>

<http://www.ncbi.nlm.nih.gov/pubmed/21270624>

<http://www.ncbi.nlm.nih.gov/pubmed/21364036>

<http://www.ncbi.nlm.nih.gov/pubmed/17396134>

<http://www.ncbi.nlm.nih.gov/pubmed/20980167>

<http://www.ncbi.nlm.nih.gov/pubmed/21593862>

<http://www.ncbi.nlm.nih.gov/pubmed/15701823>

<http://www.ncbi.nlm.nih.gov/pubmed/7059456>

<http://www.ncbi.nlm.nih.gov/pubmed/1244564>

<http://www.ncbi.nlm.nih.gov/pubmed/9262252>